600713.SS SHH
NanJing Pharmaceutical Company Limited
1W: -0.4%
1M: -4.4%
3M: -1.2%
YTD: -10.7%
1Y: -4.4%
3Y: +2.9%
5Y: +16.0%
¥5.00 ($0.75)
+0.06 (+1.21%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$2.1B
+12.0% ▲
5Y CAGR: +16.3%
Capital Expenditures
$545M
-244.3% ▼
5Y CAGR: +12.6%
Free Cash Flow
$1.6B
-9.0% ▼
5Y CAGR: +17.7%
Dividends Paid
$505M
+14.1% ▲
Buybacks
$2M
-1183.1% ▼
Net Change in Cash
$734M
+27.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $470M | $611M | $716M | $578M | $743M |
| Depreciation & Amort. | $129M | $241M | $260M | $270M | $269M |
| Stock-Based Comp. | $0 | $0 | $17M | $18M | $8M |
| Change in Working Capital | -$2.0B | -$503M | -$2.1B | $538M | $742M |
| Other Non-Cash Items | $273M | $346M | $460M | $503M | $374M |
| Operating Cash Flow | -$1.2B | $695M | -$682M | $1.9B | $2.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$247M | -$307M | -$155M | -$158M | -$545M |
| Acquisitions (Net) | -$29M | -$2M | $122M | -$3K | $0 |
| Investment Purchases | $286M | $0 | -$122M | -$24M | -$28M |
| Investment Sales | $21M | $46M | $3M | $2M | $3M |
| Other Investing | -$247M | $38M | $93M | $27M | $7M |
| Investing Cash Flow | -$216M | -$225M | -$59M | -$153M | -$562M |
| — Financing Activities — | |||||
| Net Debt Issuance | $1.1B | $1.1B | $75M | -$461M | -$181M |
| Stock Repurchased | $0 | $0 | $0 | -$165K | -$2M |
| Dividends Paid | -$353M | -$935M | -$483M | -$588M | -$505M |
| Other Financing | -$14M | -$138M | $874M | -$130M | -$152M |
| Financing Cash Flow | $749M | $31M | $467M | -$1.2B | -$840M |
| Net Change in Cash | -$619M | $502M | -$275M | $576M | $734M |
| Cash End of Period | $1.4B | $1.9B | $1.6B | $2.2B | $2.9B |
| Free Cash Flow | -$1.4B | $389M | -$838M | $1.7B | $1.6B |